Open AccessHigher efavirenz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutations
Author(s) -
Daniel Gonzàlez de Requena,
Óscar Gallego,
Angélica Corral,
Inmaculada Jiménez-Nácher,
Vincent Soriano
Publication year - 2004
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/00002030-200410210-00017
Subject(s) - efavirenz , reverse transcriptase , virology , reverse transcriptase inhibitor , nucleoside reverse transcriptase inhibitor , nucleoside analogue , nucleoside , virus , biology , sida , medicine , viral disease , rna , viral load , genetics , antiretroviral therapy , gene
We examined the influence of both efavirenz plasma concentrations and non-nucleoside reverse transcriptase (NNRTI) resistance mutations on the antiviral activity of efavirenz in patients experiencing early virological failure under nevirapine-containing regimens. Up to 41% of patients reach less than 50 copies/ml at 48 weeks. No association was found between the presence of NNRTI resistance mutations and virological outcome. Nevertheless, patients responding virologically and carrying NNRTI-resistant viruses had higher efavirenz levels than those who did not respond.